Quantitative Investment Management LLC Makes New Investment in Stryker Corporation $SYK

Quantitative Investment Management LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,942 shares of the medical technology company’s stock, valued at approximately $1,870,000.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at about $1,822,272,000. Bank of America Corp DE purchased a new stake in shares of Stryker in the 2nd quarter valued at $1,404,284,000. Auto Owners Insurance Co boosted its stake in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Stryker during the 2nd quarter valued at $707,212,000. Finally, Jupiter Topco LLC purchased a new position in Stryker in the 2nd quarter worth $681,581,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $324.32 on Tuesday. The firm has a market cap of $124.40 billion, a PE ratio of 33.61, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $329.49 and its two-hundred day simple moving average is $331.03.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Truist Financial raised their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada decreased their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Buying and Selling at Stryker

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.